The HistoGeneX team consists of industry veterans representing multiple sectors. Collectively, you will be working with a team who has pioneered global scientific and enterprise innovations and accomplishments.  We believe these perspectives and experience are vital contributors to the success of clinical development programs.

 Mark Kockx, MD, PhD. Founder, Chief Executive Officer & Chief Medical Officer


Dr. Mark Kockx founded Histogenex Laboratories in 2001. At the University of Antwerp, Belgium, Dr. Kockx pioneered methodologies to elucidate apoptotic and cytostatic response of cancer patients after treatments with targeted therapies. His subsequent collaborations with global pharmaceutical companies led to the founding of Histogenex Laboratories.

Dr. Kockx is an internationally recognized pathologist-scientist who has operated on the forefront of personalized medicine developments. He continues to lead initiatives to standardize biomarker analysis practices in addition to adapting novel technologies. Dr. Kockx has been extensively involved with the clinical trials that led to the approval of well-known targeted therapies such as EGFR, BRAF and MEK inhibitors. His current passions are two fold. He is introducing practices and workflows for next generation IHC, combining innovations of multiplex staining, quantification and image capture. He has also developed an Immunomics program, a state of the art biomarker program that supports the evolving and numerous needs of immunotherapy development.

Dirk Hendriks, PharmD, PhD, Founder, Chief Financial Officer & Director Strategic Business Development


Dr. Dirk Hendriks is a co-founder of HistoGeneX. In addition to serving as the financial officer and directing the strategic business development at HistoGeneX, Dr. Hendriks is a clinical pathologist and professor of Medical Biochemistry at the University of Antwerp in Belgium. He maintains an active lecturing schedule covering medical biochemistry, clinical pathology and laboratory management courses. In his university group, prof. Hendriks studies the development of new fibrinolytic mechanisms and drugs for the treatment of thrombo-embolic diseases.

His business experience includes extensive deal-structuring collaborations with the pharmaceutical Industry and also with strategic vendors. Previously, Dr. Hendriks has also successfully founded clinical pathology laboratories in the Antwerp area with subsequent mergers and acquisition transactions of these entities.

 Christopher Ung, MSc, MBA. Chief Business Officer

CHRISTOPHER 1C1A0620Mr. Christopher Ung has served in the companion diagnostics field since its inception and is one of the original pioneers of the personalized medicine field. He led the global commercialization efforts of the HercepTest™ and pharmDx EGFR companion diagnostic assays and continues to lead and implement global biomarker strategies for drug development projects. He has established several global companion diagnostic partnerships that have played a pivotal role in targeted therapy development and has set up CAP, CLIA laboratories in the US, Scotland, China, and Singapore.

Mr. Ung leads the development and execution of HistoGeneX’s strategic and business initiatives, leveraging the company’s solid tumor and anatomic pathology services. Prior to joining HistoGeneX, he was Vice President of Strategic Business & Operations at Quintiles, Chief Operating Officer for Targeted Molecular Diagnostics and Chairman of the Pathology Business Group at DAKO.